Abstract:Mingxin Cao, 1, &ast Enyu Shi, 1, &ast Hanping Wang, 1 Lujia Mao, 1 Qiqi Wu, 1 Xinming Li, 2 Yanjie Liang, 1 Xiaoying Yang, 3 Yinsong Wang, 1, 3 Changyi Li 1 1 School and Hospital of Stomatology, Tianjin Medical University, Tianjin, 300070, People's Republic of China; 2 Tianjin Stomatological Hospital, School of Medicine, Nankai University, Tianjin Key Laboratory of Oral and Maxillofacial Function Reconstruction, Tianjin, 300041, People's Republic of China; 3 Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yinsong Wang; Changyi Li, Email ; Oral squamous cell carcinoma (OSCC) is the most common type of malignant tumor in the head and neck, with a poor prognosis mainly due to recurrence and metastasis. Classical treatment modalities for OSCC like surgery and radiotherapy have difficulties in dealing with metastatic tumors, and together with chemotherapy, they have major problems related to non-specific cell death. Molecular targeted therapies offer solutions to these problems through not only potentially maximizing the anticancer efficacy but also minimizing the treatment-related toxicity. Among them, the receptor-mediated targeted delivery of anticancer therapeutics remains the most promising one. As OSCC exhibits a heterogeneous nature, selecting the appropriate receptors for targeting is the prerequisite. Hence, we reviewed the OSCC-associated receptors previously used in targeted therapy, focused on their biochemical characteristics and expression patterns, and discussed the application potential in personalized targeted therapy of OSCC. We hope that a better comprehension of this subject will help to provide the fundamental information for OSCC personalized therapeutic planning. Keywords: oral squamous cell carcinoma, receptors, targeted therapy, active targeting, drug delivery Oral squamous cell carcinoma (OSCC), originating from the mucosa of the tongue, buccal, palate, floor of the mouth, alveolar ridge, and other parts of the oral cavity, is the most common malignant tumor in the head and neck. The newest global cancer statistics reported that OSCC accounted for over 370,000 new cancers and 170,000 cases of death. 1 Despite lots of efforts having been put on treatment of OSCC, its five-year survival rate is still no more than 50%. The leading causes for poor prognosis might be correlated to recurrence and metastasis, which could be due to incomplete resection of tumor and neglected metastases. 2,3 Developing more efficient therapeutics is essential for improving prognosis of OSCC. The principal strategies for OSCC treatment are surgery, chemotherapy, radiotherapy, or a combination of these modalities based on the severity of disease. 4,5 Surgery remains the most efficient treatment for OSCC, while it inevitably damages the functions and aesthetics of the orofacial region. 6 Moreover, together with radiotherapy, they have difficulties in dealing with metastatic tumors. 7 Chemotherapy could inhibit rapidly growing cells including those in metastatic sites via inhibiting cell growth and division. 8,9 However, its selective toxicity is relatively low, and normal cells with enhanced proliferation rates such as the hair follicles, bone marrow and gastrointestinal tract could also be harmed. 10 To alleviate toxicities to normal cells, chemotherapeutics is often used at suboptimal doses, which might lead to the final failure of treatment, and even drug resistance and metastatic disease. Therefore, there has been a great pursuit for development of targeted anticancer drugs to increase the selective toxicity in cancer therapy. At present, two targeted approaches are being explored for improving the selective toxicity. One is developing newer drugs that alter specific signaling pathways of cancer cells. 11,12 For example, bevacizumab, a monoclonal antibody that directly targets vascular endothelial growth factor receptor (VEGFR), suppresses functions of all VEGF-A isoforms and blocks correlated downstream signaling, leading to cell-cycle arrest, apoptosis and anti-angiogenesis. 13 However, researches for these molecular targeted therapies will not be pressed ahead further, as these may cause a series of adverse effects in normal cells that usually distinct from classical cytotoxic chemotherapy. 14 The other emerging one is targeted delivery of anticancer drugs to cancer region, increasing the drug dosages that reach t -Abstract Truncated-

Network pharmacology and molecular docking to explore the potential molecular mechanism of chlorogenic acid treatment of oral squamous cell carcinoma

Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature

Molecular Targets of Plant-Derived Bioactive Compounds in Oral Squamous Cell Carcinoma

Application of Natural Medicinal Plants Active Ingredients in Oral Squamous Cell Carcinoma

Using network pharmacological analysis and molecular docking to investigate the mechanism of action of quercetin’s suppression of oral cancer

Molecular mechanisms underlying the epigallocatechin-3-gallate-mediated inhibition of oral squamous cell carcinogenesis

Identification of Metabolism-Associated Biomarkers for Early and Precise Diagnosis of Oral Squamous Cell Carcinoma

Searching for New Molecular Targets for Oral Squamous Cell Carcinoma with a View to Clinical Implementation of Precision Medicine

Elucidating the Anticancer Mechanisms of Cinnamoyl Sulfonamide Hydroxamate: Insights From DNA Content Analysis and Gene Expression Profiling in Squamous Cell Carcinoma

Oral squamous cell carcinomas: state of the field and emerging directions

A Graphene-Based Lipid Modulation Nanoplatform for Synergetic Lipid Starvation/Chemo/Photothermal Therapy of Oral Squamous Cell Carcinoma

Comprehensive insights into oral squamous cell carcinoma: Diagnosis, pathogenesis, and therapeutic advances

An Integrated Approach of Network Pharmacology, Bioinformatics, Molecular Docking, and Experimental Verification Uncovers Prunellae Spica as the potential Medicine of Prognosis Improvement for Oral Squamous Cell Carcinoma

New Insights for an Advanced Understanding of the Molecular Mechanisms in Oral Squamous Cell Carcinoma

Mechanisms Involved in Therapeutic Effects of Scutellaria baicalensis Georgi in Oral Squamous Cell Carcinoma Based on Systems Biology and Structural Bioinformatics Approaches

Network pharmacology and transcriptomics reveal the mechanisms of FFBZL in the treatment of oral squamous cell carcinoma

[Clinical Analysis of 318 Cases of Oropharyngeal Squamous Cell Carcinoma].

Huanglianjiedu Decoction as an effective treatment for oral squamous cell carcinoma based on network pharmacology and experimental validation

Anticancer Potential of Quercetin on Oral Squamous Cell Carcinoma: A Scoping Review and Molecular Docking

Current trends of targeted therapy for oral squamous cell carcinoma

Aqueous Extract of Sparganii Rhizoma and Curcumae Rhizoma Induces Apoptosis and Inhibits Migration in Human Oral Squamous Cell Carcinoma